Zhen Su, Chief Executive Officer and Member Board of Directors at Marengo Therapeutics, shared on LinkedIn:
“Proud moment for the Marengo team!
Interim Phase 2 results from STARt-002 have been selected for an oral presentation at SITC 2026.
STARt-002 is the first clinical study to combine a Vβ6-selective T-cell agonist with an ADC, pairing Invikafusp alfa with TRODELVY in metastatic breast cancer. Our goal is to bring next-generation precision IO to patients who don’t benefit from PD-1 therapy.
Thank you to Steven Isakoff, Erika Hamilton, FASCO, our investigators, the patients and families in the study, and our partner Gilead Sciences.
See you in Phoenix on November 7!”
Society for Immunotherapy of Cancer (SITC) added:
“Congratulations Zhen Su, and Marengo Therapeutics! Can’t wait to see you Phoenix and hear this presentation!”
Read the full article here.
Register for SITC 2026 here.
Read more articles about Society for Immunotherapy of Cancer (SITC) on OncoDaily.